Literature DB >> 15794772

Peyronie's disease: the epidemiology, aetiology and clinical evaluation of deformity.

Christopher J Smith1, Chelsea McMahon, Ridwan Shabsigh.   

Abstract

There is a wide variety of topics covered in this section. The epidemiology, aetiology and clinical evaluation of the deformity in Peyronie's disease is described, followed by a discussion of recent advances in the biology of diabetes-associated bladder complications. Bladder cancer and its molecular prognostic factors are presented, and the section ends with an in-depth presentation of an evidence-based approach to the understanding of the pharmacological class effect in the management of prostatic diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15794772     DOI: 10.1111/j.1464-410X.2005.05391.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  7 in total

Review 1.  Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Nat Rev Urol       Date:  2010-03-09       Impact factor: 14.432

2.  Corporoplasty with small soft axial prostheses (VIRILIS I®) and bovine pericardial graft (HYDRIX®) in Peyronie's disease.

Authors:  Alessandro Zucchi; Mauro Silvani; Stefano Pecoraro
Journal:  Asian J Androl       Date:  2013-01-28       Impact factor: 3.285

3.  Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study.

Authors:  M Shirazi; A R Haghpanah; M Badiee; M A Afrasiabi; S Haghpanah
Journal:  Int Urol Nephrol       Date:  2009-02-06       Impact factor: 2.370

Review 4.  Comparing and Contrasting Peyronie's Disease Guidelines: Points of Consensus and Deviation.

Authors:  Madeleine G Manka; Lindsay A White; Faysal A Yafi; John P Mulhall; Laurence A Levine; Matthew J Ziegelmann
Journal:  J Sex Med       Date:  2021-01-07       Impact factor: 3.802

5.  A Population-Based Study of Peyronie's Disease: Prevalence and Treatment Patterns in the United States.

Authors:  Dana Britt Dibenedetti; Dat Nguyen; Laurie Zografos; Ryan Ziemiecki; Xiaolei Zhou
Journal:  Adv Urol       Date:  2011-10-23

6.  The Efficacy of Medical Treatment of Peyronie's Disease: Potassium Para-Aminobenzoate Monotherapy vs. Combination Therapy with Tamoxifen, L-Carnitine, and Phosphodiesterase Type 5 Inhibitor.

Authors:  Tae Yong Park; Hyeong Guk Jeong; Jong Jin Park; Ji Yun Chae; Jong Wook Kim; Mi Mi Oh; Hong Seok Park; Je Jong Kim; Du Geon Moon
Journal:  World J Mens Health       Date:  2016-04-30       Impact factor: 5.400

7.  Sonographic patterns of Peyronie's disease in patients with absence of palpable plaques.

Authors:  Lucio Dell'Atti; Andrea Benedetto Galosi
Journal:  Int Braz J Urol       Date:  2018 Mar-Apr       Impact factor: 1.541

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.